'Tomudex' (ZD1694): A novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours

Annals of Oncology

Volumn 7, Issue 2, 1996, Pages 179-182

  Cunningham, D ^a   Zalcberg, J ^b   Smith, I ^b   Gore, M ^b   Pazdur, R ^b   Burris III, H ^b   Meropol, N J ^b   Kennealey, G ^b   Seymour, L ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NONE

Author keywords

'Tomudex' (ZD1694); Colorectal cancer (advanced); Inhibitor; Thymidylate synthase

Indexed keywords

RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR;

ALOPECIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LIVER TOXICITY; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; VOMITING;

EID: 0029931840     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010546     Document Type: Article

References (10)

1. Jackman A, Gibson W, Brown M et al. The role of the reduced folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Adv Exp Med Biol 1993; 339: 265-76.
2. Clarke SJ, Ward J, de Boer M et al. Phase I study of the new thymidylate synthase inhibitor TOMUDEX (ZD16194) in patients with advanced malignancy. Ann Oncol 1994; 5 (Suppl 5): 132.
3. Fleming TR. One sample testing for phase II clinical trials. Biometrics 1982; 38: 143-51.
4. WHO. WHO Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organisation 1979.
5. Hayward JL, Carbone PP, Henson JC et al. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
6. Wittes RE (ed). Manual of Oncologic Therapeutics. Philadelphia: JB Lippincott 1989/1990.
7. The Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. 41st World Medical Assembly, Hong Kong 1989.
8. The Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
9. Poon MA, O'Connel MJ, Wieand HS et al. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved efficacy in advanced colorectal cancer. J Clin Oncol 1991; 9: 1967-72.
10. Petrelli N, Douglas HO, Herrera L et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomised phase III trial. J Clin Oncol 1989; 7: 1419-26.